GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Degree of Financial Leverage

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Degree of Financial Leverage : 0.00 (As of Mar. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Checkmate Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2022 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Checkmate Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

CMPI's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.96
* Ranked among companies with meaningful Degree of Financial Leverage only.

Checkmate Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Checkmate Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Degree of Financial Leverage Chart

Checkmate Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Degree of Financial Leverage
- - - -

Checkmate Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Checkmate Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Checkmate Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkmate Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's Degree of Financial Leverage falls into.



Checkmate Pharmaceuticals Degree of Financial Leverage Calculation

Checkmate Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2022 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.92 (Mar. 2022) / -2.508 (Mar. 2021) - 1 )/( -63.175 (Mar. 2022) / -43.262 (Mar. 2021) - 1 )
=0.1643/0.4603
=0.36***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Checkmate Pharmaceuticals  (NAS:CMPI) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Checkmate Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash director, officer: Chief Executive Officer C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg director, officer: Chief Scientific Officer C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski officer: Chief Financial Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger director, officer: President and CEO C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono director C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff director C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan officer: Chief Operating Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary officer: Chief Business Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of venBio Partners LLC

By GuruFocus Research GuruFocus Editor 08-16-2022